Renalytix plc (RNLXY) stock
RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Số liệu tài chính tới Q1 năm tài chính 2025, quý kết thúc ngày Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Renalytix ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Renalytix's ebitda for the twelve months ending Sep 30, 2024 was -$24.52M. For fiscal 2024 it was -$29.24M. The highest annual figure on record is -$10.25M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | -$29.24M | – |
| FY2023 | Jun 30, 2023 | -$41.71M | – |
| FY2022 | Jun 30, 2022 | -$52.69M | – |
| FY2021 | Jun 30, 2021 | -$31.63M | – |
| FY2020 | Jun 30, 2020 | -$10.25M | – |
| FY2019 | Jun 30, 2019 | -$42.31M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$4.03M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$5.47M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$6.48M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$8.53M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$8.76M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$9.81M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$10.79M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$9.52M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$11.59M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$12.92M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$14.41M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$13.68M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$11.70M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$9.73M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$7.99M | – |
See a number that looks wrong?